Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
Japan · Delayed Price · Currency is JPY 2,388.50
-95.00 (-3.83%)
Jul 31, 2026, 3:30 PM JST
Rohto Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 343,725 | 308,625 | 270,840 | 238,664 | 199,646 | |
Revenue Growth | 11.37% | 13.95% | 13.48% | 19.54% | 10.13% |
Cost of Revenue | 151,030 | 133,686 | 113,554 | 101,243 | 83,157 |
Gross Profit | 192,695 | 174,939 | 157,286 | 137,421 | 116,489 |
Selling, General & Admin | 128,132 | 115,521 | 101,377 | 89,859 | 76,435 |
Research & Development | 13,727 | 14,912 | 13,390 | 11,065 | 8,740 |
Amortization of Goodwill & Intangibles | 2,048 | 1,523 | 436 | 383 | 457 |
Operating Expenses | 151,989 | 136,474 | 117,119 | 103,883 | 88,297 |
Operating Income | 40,706 | 38,465 | 40,167 | 33,538 | 28,192 |
Interest Expense | -1,284 | -949 | -196 | -247 | -248 |
Interest & Investment Income | 5,945 | 1,922 | 2,009 | 2,285 | 751 |
Earnings From Equity Investments | 92 | 166 | -289 | 56 | 143 |
Currency Exchange Gain (Loss) | 1,338 | 516 | 447 | - | - |
Other Non Operating Income (Expenses) | 1,172 | 311 | 294 | -64 | 245 |
EBT Excluding Unusual Items | 47,969 | 40,431 | 42,432 | 35,568 | 29,083 |
Gain (Loss) on Sale of Investments | -907 | 1,896 | -798 | -160 | -368 |
Asset Writedown | -241 | -175 | -348 | -1,338 | -892 |
Other Unusual Items | -1 | 179 | 230 | 219 | 129 |
Pretax Income | 46,820 | 42,331 | 41,516 | 34,289 | 27,952 |
Income Tax Expense | 12,404 | 11,379 | 10,123 | 7,860 | 6,803 |
Earnings From Continuing Operations | 34,416 | 30,952 | 31,393 | 26,429 | 21,149 |
Minority Interest in Earnings | -169 | 54 | -457 | -52 | -131 |
Net Income | 34,247 | 31,006 | 30,936 | 26,377 | 21,018 |
Net Income to Common | 34,247 | 31,006 | 30,936 | 26,377 | 21,018 |
Net Income Growth | 10.45% | 0.23% | 17.28% | 25.50% | 25.53% |
Shares Outstanding (Basic) | 226 | 228 | 228 | 228 | 228 |
Shares Outstanding (Diluted) | 235 | 229 | 229 | 229 | 229 |
Shares Change | 2.87% | 0.04% | - | -0.00% | - |
EPS (Basic) | 151.56 | 136.11 | 135.60 | 115.62 | 92.13 |
EPS (Diluted) | 145.29 | 135.44 | 135.21 | 115.29 | 91.86 |
EPS Growth | 7.27% | 0.17% | 17.28% | 25.50% | 25.53% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 36,294 | 27,837 | 26,266 | 22,451 | 16,983 |
Free Cash Flow Per Share | 154.14 | 121.61 | 114.80 | 98.13 | 74.23 |
Dividend Per Share | 46.000 | 36.000 | 27.000 | 22.000 | 18.000 |
Dividend Growth | 27.78% | 33.33% | 22.73% | 22.22% | 28.57% |
Gross Margin | 56.06% | 56.68% | 58.07% | 57.58% | 58.35% |
Operating Margin | 11.84% | 12.46% | 14.83% | 14.05% | 14.12% |
Profit Margin | 9.96% | 10.05% | 11.42% | 11.05% | 10.53% |
Free Cash Flow Margin | 10.56% | 9.02% | 9.70% | 9.41% | 8.51% |
EBITDA | 58,083 | 51,608 | 48,854 | 41,339 | 35,865 |
EBITDA Margin | 16.90% | 16.72% | 18.04% | 17.32% | 17.96% |
D&A For EBITDA | 17,377 | 13,143 | 8,687 | 7,801 | 7,673 |
EBIT | 40,706 | 38,465 | 40,167 | 33,538 | 28,192 |
EBIT Margin | 11.84% | 12.46% | 14.83% | 14.05% | 14.12% |
Effective Tax Rate | 26.49% | 26.88% | 24.38% | 22.92% | 24.34% |
Advertising Expenses | 62,602 | 57,506 | 54,219 | 46,467 | 38,114 |